Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasm Metastasis 2Small Cell Lung Carcinoma 1Sarcoma 1Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Radiotherapy 22Fluorouracil 20Oxaliplatin 19Leucovorin 14Cisplatin 14Paclitaxel 10Radiation 8Irinotecan 8Docetaxel 7Capecitabine 7Cetuximab 6Carboplatin 6pembrolizumab 5Neoadjuvant Therapy 5Trastuzumab 4Taxes 4Chemotherapy, Adjuvant 4Panitumumab 3Microarray Analysis 3Immunohistochemistry 3Folfox protocol 3Epirubicin 3Biopsy 3tucatinib 2Surgical Procedures, Operative 2Reverse Transcriptase Polymerase Chain Reaction 2Magnetic Resonance Spectroscopy 2Gene Expression Profiling 2Gefitinib 2Everolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Adenocarcinoma Of Esophagus × LY2940680 × Clear all
NCT02530437 2023-07-10

Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer

M.D. Anderson Cancer Center

Phase 1/2 Terminated
7 enrolled 11 charts
Gastrointestinal

Adenocarcinoma Of Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡